Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy
Conclusion:
No detrimental effects on cognitive status, functional outcomes, or brain imaging parameters were observed after using the HDACi RMD as latency-reversing agent with the MVA.HIVconsv vaccine in early-treated HIV-1-infected individuals. CNS safety was also confirmed after completion of the MAP.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
More News: AIDS Vaccine | Brain | Clinical Trials | HIV AIDS | Infectious Diseases | Neurology | Neuroscience | Science | Study | Vaccines